Type 2‐low asthma phenotypes by integration of sputum transcriptomics and serum proteomics
Nazanin Zounemat Kermani, Mansoor Saqi, Paul‐Michael Agapow, Stelios Pavlidis, Chih‐Hsi S. Kuo, Kai Sen Tan, Sharon Mumby, Kai Sun, Matthew J. Loza, Frédéric Baribaud, Ana R. Sousa, John Riley, Åsa M. Wheelock, Craig E. Wheelock, Bertrand De Meulder, Jim Schofield, Stephany Sánchez‐Ovando, Jodie L. Simpson, Katherine J. Baines, Peter Wark, Charles Auffray, Sven‐Erik Dahlén, Peter J. Sterk, Ratko Djukanović, Ian M. Adcock, Yike Guo, Kian Fan Chung, U‐BIOPRED Project Team
Abstract
Ratko Djukanović has consulted and presented at symposia organised by TEVA, Novartis, GlaxoSmithKline and AstraZeneca and has shares in and consults for Synairgen; Dr Asa Wheelock report remuneration from AstraZenica and Harvard Medical School for speaking engagements on SNF-clustering in COPD.; Charles Auffray reports grants from Innovative Medicine Initiative; Kian Fan Chung has received honoraria for participating in Advisory Board meetings of the pharmaceutical industry regarding treatments for asthma and chronic obstructive pulmonary disease and has also been remunerated for speaking engagements; Ian Adcock has received grants from Advisory Board meetings with pharmaceutical companies GSK, A-Z, Novartis, Boehringer Ingelheim and Vectura, and grants on asthma and COPD from Pfizer, GSK, MRC, EU, BI and IMI; Peter Sterk reports grants from IMI Innovative Medicines Initiative, during the conduct of the study; Matthew Loza and Frederic Baribaud are Employees and Shareholders of Janssen Research and Development, a Johnson and Johnson company; John Riley and Ana R Sousa are employees of GSK; the rest of the authors have nothing to disclose. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.